

according to the OSHA Hazard Communication Standard

# **Belzutifan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/27/2023
4.2	09/30/2023	5276390-00014	Date of first issue: 11/14/2019

## **SECTION 1. IDENTIFICATION**

Product name	:	Belzutifan Formulation
Manufacturer or supplier's o	deta	ails
Company name of supplier	:	, , -
Address	:	126 E. Lincoln Avenue Rahway, New Jersey U.S.A. 07065
Telephone	:	908-740-4000
Emergency telephone	:	1-908-423-6000
E-mail address	:	EHSDATASTEWARD@merck.com
Recommended use of the c	hen	nical and restrictions on use
Recommended use	:	Pharmaceutical
Restrictions on use	:	Not applicable

## SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accord 1910.1200) Combustible dust	dar	ce with the OSHA Hazard Communication Standard (29 CFR
Reproductive toxicity	:	Category 2
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Blood, epididymis, Testis)
GHS label elements Hazard pictograms	:	
Signal Word	:	Warning
Hazard Statements	:	If small particles are generated during further processing, han- dling or by other means, may form combustible dust concentra- tions in air. H361fd Suspected of damaging fertility. Suspected of damaging the unborn child. H373 May cause damage to organs (Blood, epididymis, Testis) through prolonged or repeated exposure if swallowed.
Precautionary Statements	:	<ul> <li>Prevention:</li> <li>P201 Obtain special instructions before use.</li> <li>P202 Do not handle until all safety precautions have been read and understood.</li> <li>P260 Do not breathe dust.</li> <li>P280 Wear protective gloves, protective clothing, eye protection and face protection.</li> </ul>

according to the OSHA Hazard Communication Standard



## **Belzutifan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/27/2023
4.2	09/30/2023	5276390-00014	Date of first issue: 11/14/2019

## Response:

P308 + P313 IF exposed or concerned: Get medical attention.

#### Storage:

P405 Store locked up.

## Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.

: Mixture

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	35
Belzutifan	1672668-24-4	8

#### **SECTION 4. FIRST AID MEASURES**

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of
Protection of first-aiders	:	the skin. Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment



according to the OSHA Hazard Communication Standard

ersion 2	Revision Date: 09/30/2023		OS Number: 76390-00014	Date of last issue: 04/27/2023 Date of first issue: 11/14/2019
Notes	to physician	:		al for exposure exists (see section 8). ically and supportively.
ECTION	5. FIRE-FIGHTING ME	ASL	JRES	
Suital	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide ( Dry chemical	
Unsui media	itable extinguishing a	:	None known.	
Speci fightir	fic hazards during fire ng	:	concentrations, a potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a plosion hazard. bustion products may be a hazard to health.
Haza ucts	rdous combustion prod-	:	Carbon oxides Metal oxides	
Speci ods	fic extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do
	al protective equipment e-fighters	:		e, wear self-contained breathing apparatus. tective equipment.

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

according to the OSHA Hazard Communication Standard



# **Belzutifan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/27/2023
4.2	09/30/2023	5276390-00014	Date of first issue: 11/14/2019

## SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation Advice on safe handling	:	Use only with adequate ventilation. Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	:	Keep in properly labeled containers. Store locked up. Store in accordance with the particular national regulations.
Materials to avoid	:	Do not store with the following product types: Strong oxidizing agents

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	15 mg/m³ Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	5 mg/m³ Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
	15 Million particles per cubic foot Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
Dust, nuisance dust and par- ticulates	10 mg/m³ Value type (Form of exposure): PEL (Total dust) Basis: CAL PEL
	5 mg/m³ Value type (Form of exposure): PEL (respirable dust fraction) Basis: CAL PEL



according to the OSHA Hazard Communication Standard

rsion	Revision Date: 09/30/2023	SDS Number: 5276390-00014		t issue: 04/27/2023 t issue: 11/14/2019	
Comp	ponents	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cellu	lose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
			TWA (Res- pirable)	5 mg/m <sup>3</sup>	NIOSH RE
			TWA (total)	10 mg/m <sup>3</sup>	NIOSH RE
			TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
			TWÁ (respir- able fraction)	5 mg/m <sup>3</sup>	OSHA Z-1
Belzu	ıtifan	1672668-24- 4	TWA	70 µg/m3 (OEB 3)	Internal
			Wipe limit	70 µg/100 cm2	Internal
Perso	onal protective equip	containment o Minimize ope	devices).	areas (e.g., open-fa	UE
	iratory protection	maintain vapo concentration unknown, app Follow OSHA use NIOSH/M by air purifyin hazardous ch supplied resp release, expo	or exposures bell s are above reco propriate respirat respirator regula ISHA approved r g respirators aga emical is limited irator if there is a sure levels are u where air purifyi	ntilation is recommended lim ow recommended lim ommended limits or a tory protection should ations (29 CFR 1910 respirators. Protection ainst exposure to any . Use a positive press any potential for uncounknown, or any othe ing respirators may n	hits. Where are I be worn. .134) and n provided sure air ntrolled r
Hand	protection				
Ma	aterial	: Chemical-res	istant gloves		
	emarks protection	If the work en mists or aeros Wear a faces potential for c	plasses with side vironment or act sols, wear the ap hield or other ful	shields or goggles. ivity involves dusty copropriate goggles. I face protection if the he face with dusts, m	ere is a
Skin a	and body protection	Additional bo task being pe	rformed (e.g., sle	at. uld be used based u eevelets, apron, gaur osed skin surfaces.	



according to the OSHA Hazard Communication Standard

# **Belzutifan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/27/2023
4.2	09/30/2023	5276390-00014	Date of first issue: 11/14/2019
Hygie	ne measures	contaminated cl If exposure to c eye flushing sys working place. When using do Wash contamin The effective op engineering cor appropriate deg	hemical is likely during typical use, provide stems and safety showers close to the not eat, drink or smoke. ated clothing before re-use. beration of a facility should include review of strols, proper personal protective equipment, owning and decontamination procedures, ne monitoring, medical surveillance and the

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form combustible dust concentrations in air during proce- ssing, handling or other means.
Flammability (liquids)	:	Not applicable
Burning number	:	5
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available



according to the OSHA Hazard Communication Standard

# **Belzutifan Formulation**

Version 4.2	Revision Date: 09/30/2023		S Number: 76390-00014	Date of last issue: 04/27/2023 Date of first issue: 11/14/2019
	ility(ies) ater solubility	:	No data available	9
	ion coefficient: n- ol/water	:	Not applicable	
	gnition temperature	:	No data available	9
Deco	mposition temperature	:	No data available	9
	sity scosity, kinematic sive properties	:	Not applicable Not explosive	
Oxidi	zing properties	:	The substance o	r mixture is not classified as oxidizing.
Moleo	cular weight	:	No data available	9
Minim	num ignition energy	:	3 - 10 mJ Method: With ind	luctance
			10 - 30 mJ Method: Without	inductance
Partic	cle size	:	26.13 µm	

## SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. May form combustible dust concentrations in air during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation. Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

## SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

#### Acute toxicity

Not classified based on available information.



according to the OSHA Hazard Communication Standard

# **Belzutifan Formulation**

Version 4.2	Revision Date: 09/30/2023	SDS Number: 5276390-00014	Date of last issue: 04/27/2023 Date of first issue: 11/14/2019
<u>Corr</u>	<u>iponents:</u>		
Cell	ulose:		
Acut	e oral toxicity	: LD50 (Rat): > \$	5,000 mg/kg
Acut	e inhalation toxicity	: LC50 (Rat): > 5 Exposure time: Test atmosphe	:4 h
Acut	e dermal toxicity	: LD50 (Rabbit):	> 2,000 mg/kg
Belz	utifan:		
Acut	e oral toxicity	: LD0 (Rat): 200	mg/kg
		LD0 (Dog): 30	mg/kg
Skin	corrosion/irritation		
Not	classified based on ava	ailable information.	
<u>Com</u>	ponents:		

# Belzutifan:

Species	:	human skin
Method	:	EpiDerm
Result	:	No skin irritation
Remarks	:	Not classified due to lack of data.

## Serious eye damage/eye irritation

Not classified based on available information.

## Components:

## Belzutifan:

Result	:	No eye irritation
Method	:	Bovine cornea (BCOP)
Remarks	:	Not classified due to lack of data.

#### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

## **Respiratory sensitization**

Not classified based on available information.

## Components:

# Belzutifan:Test Type: Local lymph node assay (LLNA)Routes of exposure: DermalSpecies: MouseResult: Not a skin sensitizer.Remarks: Not classified due to lack of data.





sion	Revision Date: 09/30/2023	SDS Number: 5276390-00014	Date of last issue: 04/27/2023 Date of first issue: 11/14/2019
	assified based on a	vailable information.	
Comp	<u>oonents:</u>		
Cellu	lose:		
Geno	toxicity in vitro	: Test Type: Bac Result: negativ	terial reverse mutation assay (AMES) e
		Test Type: In v Result: negativ	itro mammalian cell gene mutation test e
Geno	toxicity in vivo	: Test Type: Mar cytogenetic ass Species: Mouse Application Rou Result: negativ	e ute: Ingestion
Belzu	itifan:		
Geno	toxicity in vitro	: Test Type: Ame Result: negativ	
		Test Type: Mic Test system: m Result: negativ	ammalian cells
Geno	toxicity in vivo	: Remarks: Not o	classified due to lack of data.
Carci	nogenicity		
		vailable information.	
Comp	<u>oonents:</u>		
Cellu	lose:		
Speci	es	: Rat	
Applic	cation Route	: Ingestion	
	sure time	: 72 weeks	
Resul	t	: negative	
Belzu	itifan:		
Rema	arks	: Not classified d	lue to lack of data.
IARC	J		ent at levels greater than or equal to 0.1% is confirmed human carcinogen by IARC.
OSH/		onent of this product pre 's list of regulated carcin	sent at levels greater than or equal to 0.1% is logens.
NTP		lient of this product pres as a known or anticipate	ent at levels greater than or equal to 0.1% is





## **Belzutifan Formulation**

Version 4.2	Revision Date: 09/30/2023		OS Number: 76390-00014	Date of last issue: 04/27/2023 Date of first issue: 11/14/2019
•	oductive toxicity ected of damaging fertili	ty. S	Suspected of dam	aging the unborn child.
Com	ponents:			
Cellu	llose:			
Effec	ts on fertility	:	Test Type: One Species: Rat Application Rou Result: negative	
Effec	ts on fetal development	:	Test Type: Fert Species: Rat Application Rou Result: negative	
Belzı	utifan:			
Effec	ts on fertility	:	Remarks: Inforr literature.	nation taken from reference works and the
Effec	ts on fetal development	:	Remarks: Inforr literature.	nation taken from reference works and the
Repro sessr	oductive toxicity - As- ment	:	Suspected of dauge of dauge of dauge of the second	amaging fertility. Suspected of damaging the
STO	Γ-single exposure			

Not classified based on available information.

## STOT-repeated exposure

May cause damage to organs (Blood, epididymis, Testis) through prolonged or repeated exposure if swallowed.

## **Components:**

<b>Belzutifan:</b> Routes of exposure Target Organs Assessment	<ul> <li>Ingestion</li> <li>Blood, epididymis, Testis</li> <li>Shown to produce significant health effects in animals at concentrations of &gt;10 to 100 mg/kg bw.</li> </ul>
Routes of exposure Target Organs Assessment	<ul> <li>Oral</li> <li>Blood, epididymis, Testis</li> <li>May cause damage to organs through prolonged or repeated exposure.</li> </ul>
Repeated dose toxicity	

## Components:

## Cellulose:

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg



according to the OSHA Hazard Communication Standard

Application Route       :       Ingestion         Exposure time       :       90 Days         Belzutifan:       :       90 Days         Species       :       Rat         LOAEL       :       6 mg/kg         Application Route       :       Oral         Exposure time       :       28 d         Target Organs       :       Blood, Testis, epididymis         Species       :       Rat, male         NOAEL       :       2 mg/kg         LOAEL       :       6 mg/kg         Application Route       :       Oral         Exposure time       :       13 Weeks         Target Organs       :       Blood, Central nervous system, epididy         Species       :       Rat, female         LOAEL       :       200 mg/kg         Application Route       :       Oral         Exposure time       :       13 Weeks         Target Organs       :       Blood, Central nervous system, Liver         Species       :       Dog         LOAEL       :       1 mg/kg         Application Route       :       Oral         Exposure time       :       28 d	1/14/2019
Species:RatLOAEL:6 mg/kgApplication Route:OralExposure time:28 dTarget Organs:Blood, Testis, epididymisSpecies:Rat, maleNOAEL:2 mg/kgLOAEL:6 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididySpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididySpecies:Rat, femaleLOAEL::Application Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL::Species:DogLOAEL::Species:DogLOAEL::Application Route:Dog:LOAEL::Species:Dog:LOAEL:LOAEL: <t< td=""><td></td></t<>	
LOAEL:6 mg/kgApplication Route:OralExposure time:28 dTarget Organs:Blood, Testis, epididymisSpecies:Rat, maleNOAEL:2 mg/kgLOAEL:6 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididSpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididSpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kgApplication Route:DogLOAEL::Dog:LOAEL::Dog:LOAEL::Dog:LOAEL::Dog:LOAEL::LOAEL:LOAEL:LO	
Application Route:OralExposure time:28 dTarget Organs:Blood, Testis, epididymisSpecies:Rat, maleNOAEL:2 mg/kgLOAEL:2 mg/kgLOAEL:6 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididySpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kgApplication Route:Dog:LOAEL::Dog:LOAEL:Dog:LOAEL:Dog:LOAEL:Dog:LOAEL:LOAEL:Dog:LOAEL <td:< td="">Species:Dog</td:<>	
Exposure time: 28 dTarget Organs: Blood, Testis, epididymisSpecies: Rat, maleNOAEL: 2 mg/kgLOAEL: 6 mg/kgApplication Route: OralExposure time: 13 WeeksTarget Organs: Blood, Central nervous system, epididSpecies: Rat, femaleLOAEL: 200 mg/kgApplication Route: OralExposure time: 13 WeeksTarget Organs: Blood, Central nervous system, epididSpecies: Rat, femaleLOAEL: 200 mg/kgApplication Route: OralExposure time: 13 WeeksTarget Organs: Blood, Central nervous system, LiverSpecies: DogLOAEL: 1 mg/kgApplication Route: OralExposure time: 28 dTarget Organs: BloodSpecies: DogLOAEL: DogLOAEL: 1 mg/kgSpecies: DogLOAEL: 1 mg/kg	
Target Organs:Blood, Testis, epididymisSpecies:Rat, maleNOAEL:2 mg/kgLOAEL:6 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididSpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididSpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kg	
NOAEL: 2 mg/kgLOAEL: 6 mg/kgApplication Route: OralExposure time: 13 WeeksTarget Organs: Blood, Central nervous system, epididSpecies: Rat, femaleLOAEL: 200 mg/kgApplication Route: OralExposure time: 13 WeeksTarget Organs: Blood, Central nervous system, LiverSpecies: DogLOAEL: 1 mg/kgApplication Route: OralExposure time: 28 dTarget Organs: BloodSpecies: DogLOAEL: 1 mg/kgApplication Route: OralExposure time: 28 dTarget Organs: Blood	
LOAEL:6 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididSpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:LOAEL:1 mg/kg	
Application Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididySpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kgSpecies:DogLOAEL:1 mg/kg	
Exposure time:13 WeeksTarget Organs:Blood, Central nervous system, epididSpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kgSpecies:1 orgLOAEL:1 mg/kg	
Target Organs:Blood, Central nervous system, epididSpecies:Rat, femaleLOAEL:200 mg/kgApplication Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kgSpecies:1 mg/kg	
LOAEL: 200 mg/kgApplication Route: OralExposure time: 13 WeeksTarget Organs: Blood, Central nervous system, LiverSpecies: DogLOAEL: 1 mg/kgApplication Route: OralExposure time: 28 dTarget Organs: BloodSpecies: Dog	ymis, Liver, Testis
Application Route:OralExposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kg	
Exposure time:13 WeeksTarget Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kg	
Target Organs:Blood, Central nervous system, LiverSpecies:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kg	
Species:DogLOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kg	
LOAEL:1 mg/kgApplication Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kg	
Application Route:OralExposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kg	
Exposure time:28 dTarget Organs:BloodSpecies:DogLOAEL:1 mg/kg	
Target Organs:BloodSpecies:DogLOAEL:1 mg/kg	
LÖAEL : 1 mg/kg	
LOAEL : 1 mg/kg	
5 5	
· · · · ·	
Exposure time : 13 Weeks	
Target Organs : Blood	
Aspiration toxicity	
Not classified based on available information.	
Components:	
Belzutifan:	
Not applicable	
Experience with human exposure	
Components:	
Belzutifan:	
General Information : Symptoms: Fatigue, flu-like symptoms ache, musculoskeletal pain, Nausea	, fluid retention, Head-
Ingestion : Target Organs: Blood	
Symptoms: anemia, Changes in the bl	ood count





Version 4.2	Revision Date: 09/30/2023		OS Number: 76390-00014	Date of last issue: 04/27/2023 Date of first issue: 11/14/2019
SECTION	N 12. ECOLOGICAL INF	ORI	MATION	
		-	-	
Eco	toxicity			
<u>Com</u>	ponents:			
	ulose:			
loxi	city to fish	:	Exposure time:	atipes (Japanese medaka)): > 100 mg/l 48 h d on data from similar materials
Belz	utifan:			
Toxi plan	city to algae/aquatic ts	:	10 mg/l End point: Grow Exposure time:	
			10 mg/l End point: Grow Exposure time:	
Toxi icity)	city to fish (Chronic tox-	:	Exposure time:	ales promelas (fathead minnow)): 0.52 mg/l 32 d Test Guideline 210
aqua	city to daphnia and other atic invertebrates (Chron- xicity)		Exposure time:	magna (Water flea)): 3.9 mg/l 21 d Test Guideline 211
Toxi	city to microorganisms	:		
				0
Pers	sistence and degradabi	lity		
Com	ponents:			
	ulose: legradability	:	Result: Readily	biodegradable.
-	<b>utifan:</b> legradability	:	Result: Not read	lily biodegradable.



according to the OSHA Hazard Communication Standard

## **Belzutifan Formulation**

Version 4.2	Revision Date: 09/30/2023		DS Number: 276390-00014	Date of last issue: 04/27/2023 Date of first issue: 11/14/2019
			Biodegradation: Exposure time: 18 Method: OECD T	
Bioa	ccumulative potential			
Com	ponents:			
Partit	u <b>tifan:</b> ion coefficient: n- iol/water	:	log Pow: 1.11 pH: 7	
Mobi	lity in soil			
Com	ponents:			
Belzı	utifan:			
	bution among environ- al compartments	:		est Guideline 106
Othe	r adverse effects			
No da	ata available			
SECTION	13. DISPOSAL CONSI	DEF	RATIONS	

#### **Disposal methods**

Waste from residues	:	Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## **SECTION 14. TRANSPORT INFORMATION**

## International Regulations

**UNRTDG** Not regulated as a dangerous good

IATA-DGR Not regulated as a dangerous good

#### IMDG-Code


Not regulated as a dangerous good

## Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

## **Domestic regulation**

**49 CFR** Not regulated as a dangerous good





## **Belzutifan Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/27/2023
4.2	09/30/2023	5276390-00014	Date of first issue: 11/14/2019

Special precautions for user

Not applicable

## SECTION 15. REGULATORY INFORMATION

## **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

#### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

## SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Combustible dust Reproductive toxicity Specific target organ toxicity (single or repeated exposure)
SARA 313	:	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

#### US State Regulations

#### Pennsylvania Right To Know

Cellulose	9004-34-6
D-mannitol	69-65-8
Cellulose, 2-hydroxypropyl methyl ether, acetate hydrogen	71138-97-1
butanedioate	
Belzutifan	1672668-24-4
Croscarmellose sodium	74811-65-7

#### California Permissible Exposure Limits for Chemical Contaminants

 Cellulose
 9004-34-6

 The ingredients of this product are reported in the following inventories:
 CEPA

 CEPA
 : not determined

 AICS
 : not determined

IECSC : not determined


## **SECTION 16. OTHER INFORMATION**

## Further information



according to the OSHA Hazard Communication Standard

# **Belzutifan Formulation**



OSHA Z-1 / TWA:8-hour time weighted averageOSHA Z-3 / TWA:8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-



according to the OSHA Hazard Communication Standard

## Belzutifan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/27/2023
4.2	09/30/2023	5276390-00014	Date of first issue: 11/14/2019

vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety Data Sheet		eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/

09/30/2023

:

Revision Date

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8